Table 5. Objective response rates and disease control rates in studies including poor PS patients.
| Reference | Patients | Poor PS patients | ORR | DCR | PD | Statistics PS 0-1 vs.
poor PS, (95% CI) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | PS 0-1 | Poor PS | Total | PS 0-1 | Poor PS | Total | PS 0-1 | Poor PS | ||||||
| Hasegawa, Anticancer Res 2019 (35) | 51 | 5 PS ≥2 | NA | 59% | 63% | 20% | 41% | 37% | 80% | P=0.146 | ||||
| Kuzminin, WCLC 2019 (36) | 74 | 9 PS =2 3 NE |
50%* | NA | NA | 75%* | 79%* | 33%* | 25%* | 21%* | 66%* | P=0.03 DCR | ||
| Imai, J Cancer Res Clin Oncol 2020 (39) | 47 ≥75 y | 7 PS =2; 3 PS =3 2 NE |
NA | 61%* | 43%* | NA | 89%* | 43%* | NA | 11%* | 57%* | P=0.15 RR, P=0.03 DCR | ||
| Morita, BMC Cancer 2020 (40) | 205 | 29 PS =2; 6 PS =3; 1 PS =4 |
NA | 55% | 42% | NA | 77% | 64% | NA | 23% | 36% | Multivariate: OR 1.44 (0.57–3.59), P=0.4366 for response; P=0.0832 within poor PS group, trend towards lack of response | ||
| Facchinetti, Eur J Cancer 2020 (29) | 153 | 153 PS =2 | – | – | 21% | – | – | 37% | – | – | 63% | – | ||
| Cortellini, Cancer Immunol Immunother 2020 (28) | 1026 | 179 PS ≥2 36 NE |
NA | 48%* | 25%* | NA | NA | NA | NA | NA | NA | P<0.0001, Multivariate: OR 2.60 (1.73–3.91); P<0.0001 | ||
| Alessi, J Immunother Cancer 2020 (44) | 234 | 39 PS =2 | NA | 43% | 26% | NA | NA | NA | NA | NA | NA | P=0.04 | ||
| Friedlaender, Acta Oncol 2020 (45) | 302 | 56 PS =2 | NA | 72% | 45% | NA | NA | NA | NA | NA | NA | OR 0.31 (0.17–0.57) | ||
| Seban, Cancers (Basel) 2020 (46) | 63 | 13 PS ≥2 | 58% | NA | NA | 65% | NA | NA | 35% | NA | NA | RR: OR 1.3 (0.4–4.9), P=0.69; DCR: OR 1.8 (0.5–6.3), P=0.34 | ||
| Yamaguchi, Sci Rep 2020 (50) | 48 | 12 PS =2; 6 PS =3 2 NE |
NA | 52%* | 50%* | 73% | NA | NA | NA | NA | NA | P>0.99 | ||
| Inaba‐Higashiyama, Thorac Cancer 2020 (53) | 4 | 4 PS =3 | — | — | 25%§ | — | — | 25%§ | — | — | — | — | ||
*, only TC-evaluated patients considered in calculating the rates (i.e., non evaluated patients are not included in the analyses). §, Patient with PD-L1 =100%. y, years; PS, performance status; NE, not evaluated; ORR, objective response rate; NA, not available; DCR, disease control rate; PD, progressive disease; OR, odds ratio; 95% CI, 95% confidence interval.